Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2021
This article has no abstract
Epistemonikos ID: 53eb2e5db7c0d9c4d9c647f8d9ecf5c16ed850a7
First added on: Feb 13, 2025